Translating Proteomics

Nautilus Biotechnology
Translating Proteomics

‘Translating Proteomics’ explores the science of proteomics and its growing impact on biological research, biomarker discovery, drug development, food and energy security, and a range of other timely topics. Hosts Parag Mallick Ph.D. and Andreas Huhmer Ph.D. of Nautilus Biotechnology aim to share their perspectives on important issues in proteomics, deepen your love of science, and prompt you to question assumptions about what may be possible.

Episodes

  1. A New Era In Alzheimer's Research with Sarah DeVos

    OCT 30

    A New Era In Alzheimer's Research with Sarah DeVos

    Do you have a question you'd like answered on a future episode of Translating Proteomics? Send it to translatingproteomics@nautilus.bio! On this episode of Translating Proteomics, host Andreas Huhmer discusses advances in Alzheimer’s research with special guest and Curie Bio Drug Maker in Residence, Sarah DeVos Ph.D. Their conversation focuses on: The impact of molecular diagnostics on Alzheimer’s researchRecent Alzheimer’s drug approvalsThe future of Alzheimer’s research *Small edit on Sarah's background - She did her graduate work at Washington University in St. Louis and a Postdoc at Massachusetts General Hospital* Chapters00:00 – Introduction 01:54 – Why Sarah began studying Alzheimer’s 03:39 – Current tools and needs for future Alzheimer’s diagnostics 09:52 – Recent drug approvals in the Alzheimer’s space and their relationship to diagnostics 14:26 – Is it possible to develop biomarkers that detect Alzheimer’s at its earliest stages? 16:36 – What is limiting the development of new Alzheimer’s biomarkers? 17:51 – The DIAN trials and learnings from studying dominantly inherited Alzheimer’s 19:33 – The genetics of Alzheimer’s 22:19 – Novel approaches to identifying and understanding Alzheimer’s pathology  25:54 – Where can proteomics advance Alzheimer’s research? 31:25 – The role of proteomics in Alzheimer’s animal models 34:33 – Sarah’s hopes for the next 10 years of Alzheimer’s research 41:39 - Outro ResourcesDominant Inherited Alzheimer’s Network (DIAN) trials research updates o   In the DIAN trials, researchers work with families to study various clinical and basic science aspects of dominantly inherited Alzheimer’s disease. Amyloid plaque reducing clinical trials: o   Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease (Haeberlein et al. 2022) o   Donanemab in Early Symptomatic Alzheimer Disease - The TRAILBLAZER-ALZ 2 Randomized Clinical Trial (Sims et al. 2023) o   Lecanemab in Early Alzheimer’s Disease (Van Duck et al. 2022) Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Car (Palmqvist et al. 2024) o   Clinical research into a new phospo-tau biomarker that can help physicians more effectively diagnose Alzheimer’s disease Resurrecting the Mysteries of Big Tau (Fischer and Baas 2021) o   Review covering a potentially neuro-protective form of tau called “Big tau” Integrated Proteomics to Understand the Role of Neuritin (NRN1) as a Mediator of Cognitive Resilience...

    42 min
  2. Plasma Proteomics - The Dream and the Nightmare

    OCT 28

    Plasma Proteomics - The Dream and the Nightmare

    Do you have a question you'd like answered on a future episode of Translating Proteomics? Send it to translatingproteomics@nautilus.bio! On this episode of Translating Proteomics, hosts Parag Mallick and Andreas Huhmer of Nautilus Biotechnology discuss the challenges and opportunities of plasma proteomics. Their conversation focuses on: ·      Why blood plasma may be a good source of protein biomarkers ·      Current methodologies and pitfalls in plasma proteomics ·      The path forward for plasma proteomics What is Plasma Proteomics?For those who are new to this topic, plasma is the liquid portion of the blood distinct from fractions containing red and white blood cells. Given the relatively non-invasive ways physicians can collect patient plasma, and the blood’s intimate association with tissues throughout the body, plasma is potentially an excellent source of protein biomarkers. Yet, it is quite difficult to measure the levels of all plasma proteins because their concentrations span over 12 orders of magnitude. This episode features an in-depth discussion of the ways plasma proteomics efforts have and have not lived up to the promise of biomarker discovery and what we can do to advance plasma biomarker discovery efforts in the future. Chapters00:00 – 01:01 – Intro 01:02 – 4:55 – What is the promise of plasma proteomics? 04:55  – 07:23 – Is the plasma proteome really the best source of biomarkers? 07:23 – 10:16 – How do proteins get into the blood and what are the implications for biomarker discovery? 10:16 – 13:59 – Is it clear that proteins are the best candidates for blood biomarkers? 13:59 – 19:57 – Advances in and the future of comprehensive plasma proteomics 19:57 – 22:31 – Pros and cons of fractionating the plasma proteome to discover biomarkers 22:31 – 28:14 – Progress in identifying multiomic plasma biomarkers and the path forward 28:14 – End – Outro ResourcesNano-omics: nanotechnology-based multidimensional harvesting of the blood-circulating cancerome (Gardner et al. 2022) o   Review from focused on the development multiomics liquid biopsies Multicompartment modeling of protein shedding kinetics during vascularized tumor growth (Machiraju et al. 2020) o   Work from Parag’s Lab investigating tumor protein shedding Simulation of the Protein-Shedding Kinetics of a Fully Vascularized Tumor (Frieboes et al. 2015) o   Tumor protein shedding work from Parag’s Lab Mathematical model identifies blood biomarker-based early cancer detection strategies and limitations (Hori and Gambhir et al. 2011) o   Study modeling how much protein could be shed and detected from different size tumors a href="https://pubmed.ncbi.nlm.nih.gov/12488461/" rel="noopener noreferrer"...

    29 min
  3. Protein Function 201 with Kathryn Lilley

    OCT 17

    Protein Function 201 with Kathryn Lilley

    Do you have a question you'd like answered on a future episode of Translating Proteomics? Send it to translatingproteomics@nautilus.bio! Proteins adopt a wide variety of functions depending upon factors like their location in the cell, their modifications, and the biomolecules they interact with. While many of us may have been taught that single genes produce single proteins that have single functions, protein function is far more dynamic than that. In this episode of Translating Proteomics, Nautilus Co-Founder and Chief Scientist Parag Mallick sits down with University of Cambridge Professor and proteomics expert Kathryn Lilley to discuss our evolving understanding of protein function. They cover: How they came to realize protein function is more complex than one gene, one enzyme, one functionFactors that give rise to the dynamic complexity of protein function including proteoforms, protein localization, and moonlightingSteps we can take to better understand and teach others about the complexities of protein function Research diving into the complexities of protein functionResearch from the Beltrao Lab using bioinformatics techniques to identify functional phosphosites (Ochoa et al. 2020)Work from the Lilley Lab integrating techniques to investigate ome-wide localization of both RNA and protein (Villanueva et al. 2024)Lilley Lab preprint investigated protein localization changes in a cancer cell line as a result of ionizing radiation treatment (Christopher et al. 2024).Collaborative work with the Lundberg Lab mapping subcellular proteomics (Thul et al. 2017). Additional protein function resourcesMoonProt - A database for moonlight proteins from Professor Constance Jeffrey's LabTranslating Proteomics Episode 5 - Why the Biology Surrounding Biology's Central Dogma is Wrong

    46 min

Ratings & Reviews

5
out of 5
6 Ratings

About

‘Translating Proteomics’ explores the science of proteomics and its growing impact on biological research, biomarker discovery, drug development, food and energy security, and a range of other timely topics. Hosts Parag Mallick Ph.D. and Andreas Huhmer Ph.D. of Nautilus Biotechnology aim to share their perspectives on important issues in proteomics, deepen your love of science, and prompt you to question assumptions about what may be possible.

You Might Also Like

To listen to explicit episodes, sign in.

Stay up to date with this show

Sign in or sign up to follow shows, save episodes, and get the latest updates.

Select a country or region

Africa, Middle East, and India

Asia Pacific

Europe

Latin America and the Caribbean

The United States and Canada